BioSpace News Archive

Aridis Pharmaceuticals, Inc. today announced that it has created a joint venture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Hepalink), one of China’s leading pharmaceutical companies.

A new breakthrough delivery technology that optimizes the bioavailability and absorption of nutritional supplements, medical foods, and pharmaceutical drugs is now available to consumers and health-care practitioners.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled an expanded portfolio of analytical instruments, consumables, software and services to make technology more available to scientists worldwide, enabling faster, more informed decisions based on advanced scientific data.

- COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U. - AGREEMENT COMPLEMENTS AND EXTENDS ABBOTT’S BROAD LINE OF VASCULAR CARE PRODUCTS AND DEMONSTRATES VALUE OF SURMODICS’ PROPRIETARY DRUG-DELIVERY AND WHOLE-PRODUCT SOLUTIONS STRATEGY

Houston-based foundations and organizations, along with donors from across the nation, have matched a $10 million challenge grant offered by the Richard M. Schulze Family Foundation to help build an American Cancer Society Hope Lodge facility and to fund its operating endowment.

Innovative Neulasta® Onpro® Kit is Designed to Provide the Right Dose for Patients at the Right Time

Beacon Discovery today announced the formation of a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited focused on a number of G-protein coupled receptors (GPCRs) that play an important role in the pathology of gastrointestinal disorders.

Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer’s, diabetes, lupus and cancers, among other diseases, today announced that Michael Kennedy has joined the company to lead the company’s manufacturing activities.

SQI Diagnostics Inc. (“SQI” or the “Company”) and Predictive Health Diagnostics Co. (“PHD”) today announced the validation, commercial transition, and successful installation of SQI’s automated sqidlite™ system to run PHD’s multi-biomarker cardiac event prediction assay in PHD’s CLIA laboratory in Irvine, CA, where PHD is already servicing thousands of patients annually.